Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
20051.7k citationsLisa M. McShane, Douglas G. Altman et al.JNCI Journal of the National Cancer Instituteprofile →
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
20071.7k citationsLyndsay N. Harris, Herbert A. Fritsche et al.Journal of Clinical Oncologyprofile →
REporting recommendations for tumour MARKer prognostic studies (REMARK)
20051.0k citationsLisa M. McShane, Douglas G. Altman et al.British Journal of Cancerprofile →
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
2012786 citationsDouglas G. Altman, Lisa M. McShane et al.PLoS Medicineprofile →
REporting recommendations for tumor MARKer prognostic studies (REMARK)
2006660 citationsLisa M. McShane, Douglas G. Altman et al.Breast Cancer Research and Treatmentprofile →
Reporting Recommendations for Tumor Marker Prognostic Studies
2005613 citationsLisa M. McShane, Douglas G. Altman et al.Journal of Clinical Oncologyprofile →
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
1996553 citationsD. F. Hayes, Robert C. Bast et al.JNCI Journal of the National Cancer Instituteprofile →
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration
2018315 citationsWilli Sauerbrei, Sheila E. Taube et al.JNCI Journal of the National Cancer Instituteprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Sheila E. Taube
Since
Specialization
Citations
This map shows the geographic impact of Sheila E. Taube's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheila E. Taube with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheila E. Taube more than expected).
This network shows the impact of papers produced by Sheila E. Taube. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheila E. Taube. The network helps show where Sheila E. Taube may publish in the future.
Co-authorship network of co-authors of Sheila E. Taube
This figure shows the co-authorship network connecting the top 25 collaborators of Sheila E. Taube.
A scholar is included among the top collaborators of Sheila E. Taube based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Sheila E. Taube. Sheila E. Taube is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Taube, Sheila E.. (2009). Biomarkers in Oncology. Annals of the New York Academy of Sciences. 1180(1). 111–118.6 indexed citations
8.
Harris, Lyndsay N., Herbert A. Fritsche, Robert Mennel, et al.. (2007). American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. Journal of Clinical Oncology. 25(33). 5287–5312.1670 indexed citations breakdown →
9.
McShane, Lisa M., Douglas G. Altman, Willi Sauerbrei, et al.. (2006). REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Research and Treatment. 100(2). 229–235.660 indexed citations breakdown →
10.
Altman, Douglas G., et al.. (2005). Re: Reporting recommendations for tumor marker prognostic studies (REMARK) - Reply. Oxford University Research Archive (ORA) (University of Oxford).1 indexed citations
11.
McShane, Lisa M., Douglas G. Altman, Willi Sauerbrei, et al.. (2005). REporting recommendations for tumour MARKer prognostic studies (REMARK). British Journal of Cancer. 93(4). 387–391.1034 indexed citations breakdown →
Taube, Sheila E., James W. Jacobson, & Tracy Lively. (2005). Cancer Diagnostics. PubMed. 5(6). 357–364.19 indexed citations
14.
McShane, Lisa M., Douglas G. Altman, Willi Sauerbrei, et al.. (2005). Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). JNCI Journal of the National Cancer Institute. 97(16). 1180–1184.1696 indexed citations breakdown →
Hammond, M. Elizabeth, Peter E. Barker, Sheila E. Taube, & Steven Gutman. (2003). Standard reference material for Her2 testing: report of a National Institute of Standards and Technology-sponsored Consensus Workshop.. PubMed. 11(2). 103–6.27 indexed citations
Hayes, D. F., Robert C. Bast, Christopher E. Desch, et al.. (1996). Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers. JNCI Journal of the National Cancer Institute. 88(20). 1456–1466.553 indexed citations breakdown →
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.